Starling Oncology Inc(STLN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 4 at 7:30 PM ET (Korea 9/5 08:30)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.31 | Insider Own | 36.42% | Shs Outstand | 100.5M | Perf Week | -3.89% |
| Market Cap | 0.59B | Forward P/E | - | EPS next Y | 100% | Insider Trans | 0.97% | Shs Float | 63.6M | Perf Month | 18.84% |
| Enterprise Value | 0.66B | PEG | - | EPS next Q | -0.05 | Inst Own | 37.11% | Short Float | 10.83% | Perf Quarter | 21.77% |
| Income | -0.03B | P/S | 1.01 | EPS this Y | 69.91% | Inst Trans | 3.67% | Short Ratio | 3.78 | Perf Half Y | 113.31% |
| Sales | 0.59B | P/B | - | EPS next 5Y | - | ROA | -18.06% | Short Interest | 6.88M | Perf YTD | 66.57% |
| Book/sh | -0.25 | P/C | 14.43 | EPS past 3/5Y | -37.23% -17.58% | ROE | -3407.86% | 52W High | -15.89% ($7.05) | Perf Year | 81.9% |
| Cash/sh | 0.41 | P/FCF | - | Sales past 3/5Y | 25.81% 21.8% | ROIC | -42.21% | 52W Low | 155.6% ($2.32) | Perf 3Y | 415.65% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 54.91% | Gross Margin | 14.54% | Volatility(W/M) | 5.59% 6.59% | Perf 5Y | -40.34% |
| Dividend TTM | - | EV/Sales | 1.12 | Sales Y/Y TTM | 38.38% | Oper. Margin | -4.44% | ATR (14) | 0.37 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.15 | EPS Q/Q | 46.7% | Profit Margin | -5.2% | RSI (14) | 48.73 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.36 | Sales Q/Q | 34.62% | SMA20 | -5.2% ($6.26) | Beta | 0.42 | Target Price | $9.25 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/6 | SMA50 | 3.1% ($5.75) | Rel Volume | 0.26 | Prev Close | $5.97 |
| Employees | 641 | LT Debt/Eq | - | EPS/Sales Surpr. | -25% 3.56% | SMA200 | 44.6% ($4.1) | Avg Volume(3M) | 1.82M | Price | $5.93 |
| IPO | 2020/6/4 | Option/Short | Yes/Yes | Trades | 5082 | Volume | 466,592 | Change | -0.67% |
Company
STLN is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
� A healthcare facility company that operates a network of community-based cancer treatment clinics across the United States. It pursues a value-based care model by delivering specialty treatments such as oncology services, clinical trials, and infusions at clinics near where patients live, and has expanded its clinics and network care sites across multiple states.
Over the past 1 year, on the higher side
16% below its 1-year high.
STLN has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +69.9% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +415.6% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 37.1%.
Tap to view numbers
It ranks #4 in the industry
Based on market cap of $593M.
STLN $593M PER -
HCA $88B PER 13.6
THC $21B PER 10.2
FMS $12B PER 11.7
FAQ
What kind of company is STLN?
STLN belongs to the Healthcare sector and operates in the Medical Care Facilities industry.
What is the market cap of STLN?
The market cap of STLN is approximately $593M, ranking 3,120 within its sector.
What is the 52-week high and low for STLN?
STLN has recorded a 52-week high of $7.05 and a low of $2.32.
